- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.09. | Novartis puts MS advocacy on the podium through social media partnership with British Olympian | ||
| 03.09. | FDA files reveal lingering concerns, contrasting views behind Replimune melanoma nod | ||
| 03.09. | Akeso, Summit's ivonescimab extends lives in Keytruda head-to-head trial. What now? | ||
| 02.09. | ARPA-H puts up $125M to bankroll personalized RNA-based drug production | ||
| 02.09. | Novartis telegraphs 130 job cuts amid biologics rethink in Switzerland | ||
| 02.09. | Cellares downsizes New Jersey operations after losing BMS cell therapy contract | ||
| 02.09. | Trump GLP-1 update teases blockbuster annual sales for Lilly from Medicare program: analyst | ||
| 01.09. | Regulatory tracker: Another Tavneos domino falls as UK rescinds authorization | ||
| 01.09. | Bausch + Lomb survey reveals low dry eye awareness for perimenopausal, postmenopausal women | ||
| 01.09. | Novartis claims MS win as Rhapsido clears phase 3 with 'no liver safety signal' | ||
| 01.09. | What's Next in Immuno-Oncology - A Visionary Conversation with Dr Ira Mellman | ||
| 31.08. | CDMO Lonza hones commercial focus with company vet's return to new role | ||
| 31.08. | Ascendis to pay 20% Yuviwell royalties in patent settlement with BioMarin | ||
| 31.08. | B. Braun adds to a string of IV solution recalls in US | ||
| 31.08. | Jazz's Ziihera secures 2nd survival win to solidify its HER2-positive stomach cancer status | ||
| 29.08. | ESC: AstraZeneca, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM | ||
| 28.08. | Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients | ||
| 28.08. | MrBeast, Snapchat, AI and more: Pharma marketing's pulse check | ||
| 28.08. | Biogen enlists lupus patient advocate to share social media story of resilience | ||
| 28.08. | Stephen Farquhar takes over as CEO of Publicis Health Media | ||
| 28.08. | Omnicom PR consultancy injects new leadership into pharma push | ||
| 27.08. | BMS splashes out $173M to build 2nd radiopharmaceutical plant in Indiana | ||
| 27.08. | As RevMed preps for 'historic' pancreatic cancer launch, questions linger on the ground | ||
| 27.08. | PhRMA's Medicare price negotiation suit rebuffed in latest blow to industry IRA challenge | ||
| 27.08. | Amgen, AstraZeneca's Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.